MX2022001020A - Composicion y metodo para promover la cicatrizacion de heridas. - Google Patents

Composicion y metodo para promover la cicatrizacion de heridas.

Info

Publication number
MX2022001020A
MX2022001020A MX2022001020A MX2022001020A MX2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A MX 2022001020 A MX2022001020 A MX 2022001020A
Authority
MX
Mexico
Prior art keywords
wound healing
composition
promote wound
construct
promote
Prior art date
Application number
MX2022001020A
Other languages
English (en)
Spanish (es)
Inventor
Richard D Minshall
Zhenlong Chen
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2022001020A publication Critical patent/MX2022001020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2022001020A 2019-07-29 2020-07-28 Composicion y metodo para promover la cicatrizacion de heridas. MX2022001020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962879717P 2019-07-29 2019-07-29
PCT/US2020/043813 WO2021021774A1 (en) 2019-07-29 2020-07-28 Composition and method for promoting wound healing

Publications (1)

Publication Number Publication Date
MX2022001020A true MX2022001020A (es) 2022-04-06

Family

ID=72047146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001020A MX2022001020A (es) 2019-07-29 2020-07-28 Composicion y metodo para promover la cicatrizacion de heridas.

Country Status (7)

Country Link
US (1) US20220265759A1 (cg-RX-API-DMAC7.html)
EP (1) EP4003393A1 (cg-RX-API-DMAC7.html)
JP (1) JP7636812B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220042200A (cg-RX-API-DMAC7.html)
CA (1) CA3148980A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022001020A (cg-RX-API-DMAC7.html)
WO (1) WO2021021774A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116121305B (zh) * 2023-01-03 2024-11-22 广州医科大学附属第五医院 间充质干细胞在糖尿病相关疾病中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
JPS6229997A (ja) 1985-04-08 1987-02-07 Sankyo Co Ltd C末端にプロリンアミドを有するペプチドの製法
US4978532A (en) 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5580751A (en) 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
CA2115159A1 (en) 1991-08-08 1993-02-09 Jeffrey A. Bibbs Production of peptide amides
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
US5709878A (en) 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
AUPP697698A0 (en) * 1998-11-06 1998-12-03 St. Vincent's Institute Of Medical Research Regulation of enzyme activity
KR20050042788A (ko) * 2002-08-16 2005-05-10 쉐링 악티엔게젤샤프트 유전자 요법에 유용한 eNOS 돌연변이체
WO2004064833A1 (en) 2003-01-24 2004-08-05 Connetics Australia Pty Ltd. Clindamycin phosphate foam
US20060287234A1 (en) 2005-06-17 2006-12-21 Genentech, Inc. Wound healing
CN101517078A (zh) 2006-05-31 2009-08-26 貝丝以色列女执事医疗中心 诊断和治疗妊娠并发症的方法
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2009012435A1 (en) 2007-07-19 2009-01-22 The Trustees Of The University Of Pennsylvania Conformational entropy in molecular recognition
WO2011062155A1 (ja) 2009-11-19 2011-05-26 タカラバイオ株式会社 変異型Gagタンパク質をコードする核酸

Also Published As

Publication number Publication date
US20220265759A1 (en) 2022-08-25
KR20220042200A (ko) 2022-04-04
WO2021021774A1 (en) 2021-02-04
EP4003393A1 (en) 2022-06-01
JP2022543056A (ja) 2022-10-07
CA3148980A1 (en) 2021-02-04
JP7636812B2 (ja) 2025-02-27

Similar Documents

Publication Publication Date Title
MX2020013583A (es) Anticuerpos il-11.
CL2019002542A1 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
CL2021000751A1 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap
MX2020013468A (es) Anticuerpos il-11ra.
BR112020015308A8 (pt) Proteínas f de rsv estabilizadas e usos das mesmas
HN2010001435A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
AR092118A1 (es) Cepa de bacillus sp. con actividad antifungica, antibacteriana y promotora del crecimiento
EA201170349A1 (ru) Модуляторы mif
CL2018000671A1 (es) Expresión de proteínas recombinantes en pupas de trichoplusia ni
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
MX2013010360A (es) Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
CO2019009612A2 (es) Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
ECSP17029287A (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
EA200971077A1 (ru) Гетероциклические модуляторы киназы
MX2013002255A (es) Moduladores de proteina de notum y metodos de uso.
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
CU20120018A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
CR20110630A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
EA200700717A1 (ru) Сульфонамиды
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CO2022002898A2 (es) Composiciones que comprenden tigolaner para el control de parásitos